ClinicalTrials.gg
RecruitingNCT07510087GR-QoLUpdated Apr 6, 2026

Glaucoma Related Quality of Life

An observational study in Glaucoma, sponsored by Marc Toeteberg-Harms. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Marc Toeteberg-Harms · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 490 studies in Glaucoma with a site in United States — 75 open to participants now, 94 under way, 5 of them phase 3. Glaucoma · United States.

Planned enrollment
3rd of 110
5,000 · median 100
Started
2024
with 20 others
Observational
110 of 490
18 open now
Primary completion
2026-11
later than 25 of 93 live
Registered
433rd of 490
by date

Among the 490 studies in Glaucoma with a site in United States, this one is the 3rd largest by planned enrollment of the 110 observational ones that give a count, is one of 21 that started in 2024, is one of 110 observational ones, reaches primary completion later than 25 of the 93 other live ones, and was the 433rd registered.

Glaucoma

1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

75 of the 490 studies in Glaucoma with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 490 studies in Glaucoma with a site in United States, or all of them as a file.
02

Study summary

Subjects with a diagnosis of glaucoma will be handed out different quality of life related questionnaires and their score will be evaluated at baseline and 3-6 months after treatment or surgery was initiated/performed.

03

Conditions studied

  • Glaucoma

Browse trials for

Keywords

  • glaucoma
  • quality of life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

any patient with a diagnosis of glaucoma treated or evaluated for glaucoma at the Dept. of Ophthalmology \& Visual Sciences, University of Iowa, Iowa City, IA, USA

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of glaucoma (open- as well as closed-angle glaucoma, primary and secondary glaucomas)
  • 18 years of age or older with no upper limit
  • male and female subjects

Exclusion criteria

Exclusion:

  • absence of a diagnosis of glaucoma
  • less than 18 years of age
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Study Arm (glaucoma)

    subjects with a diagnosis of glaucoma

    Other: GQL-15 · Other: Glaucoma Symptom Scale · Other: NEI Vision Function Questionnaire · Other: Ocular Surface Disease Index

Interventions

  • OtherGQL-15

    GQL-15 questionnaire

  • OtherGlaucoma Symptom Scale

    GSS questionnaire

  • OtherNEI Vision Function Questionnaire

    Vision function questionnaire

  • OtherOcular Surface Disease Index

    OSDI questionnaire

06

What researchers measure

Primary outcomes

  1. Ocular Surface Disease Index (OSDI)

    The OSDI© is assessed on a scale of 0 to 4, with higher scores representing greater disability. The index demonstrates sensitivity and specificity in distinguishing between normal subjects and patients with dry eye disease. The OSDI© is a valid and reliable instrument for measuring dry eye disease (normal, mild to moderate, and severe) and effect on vision-related function.

    Time frame: At baseline and 3-6 months after glaucoma treatment (i.e. drops, SLT, or surgery) was initiated/performed.

  2. Glaucoma Symptom Scale (GSS)

    The Glaucoma Symptom Scale (GSS; Lee et al., 1998) was developed as a brief symptom survey specific for persons with glaucoma. The GSS consists of a 10-item scale developed from a modified version of a symptom checklist that address ocular complaints, some of a nonvisual nature and some of a visual nature, common to patients with glaucoma. Items are scored from 0 to 100, where 100 represents the absence of symptoms and 0 represents severe, bothersome symptoms.

    Time frame: At baseline and 3-6 months after glaucoma treatment (i.e. drops, SLT, or surgery) was initiated/performed.

  3. National Eye Institute Visual Function Questionaire (NEI VFQ)

    Vision-specific instrument designed to measure vision-related quality of life (VRQoL) in adults, incorporating body, activity, and participation content according to the WHO ICF Framework in order to measure the effects of a variety of ocular conditions on daily functioning and QOL. It was originally designed as a 51-point questionnaire and is currently available in both self-administered and interview-based formats. The raw scores are converted to a 0-100 scale; after reverse scoring, a high score (100) indicates better vision-specific quality of life, while a low score (0) indicates poor function.

    Time frame: At baseline and 3-6 months after glaucoma treatment (i.e. drops, SLT, or surgery) was initiated/performed.

  4. Glaucoma Quality of Life-15 (GQL-15)

    The Glaucoma Quality of Life-15 (GQL-15) is a validated 15-item, self-report questionnaire used to measure visual disability and quality of life (QoL) in glaucoma patients. It covers four key areas-peripheral vision, central/near vision, glare/dark adaptation, and outdoor mobility-using a 5-point scale (1=no difficulty to 5=severe difficulty).

    Time frame: At baseline and 3-6 months after glaucoma treatment (i.e. drops, SLT, or surgery) was initiated/performed.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — data will be stored anonymously without patient identifier. It can be shared on a case by case decision.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Nov 2026, 23 months after the start.

Of 111 non-industry observational studies under Glaucoma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 208. This study's planned 23 months is below that.

Counting every sponsor, half of 135 studies reached it within 31 months; a quarter within 11 and three quarters within 208.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2024
First posted
Apr 3, 2026
StartActual
Dec 30, 2024
Primary completionEst.
Nov 30, 2026
CompletionEst.
May 30, 2027
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07510087
Lead sponsor
Marc Toeteberg-Harms
Responsible party
Marc Toeteberg-Harms (Associate Professor, University of Iowa) — Sponsor-investigator
First posted
Apr 3, 2026
Start date
Dec 30, 2024
Primary completion
Nov 30, 2026 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Apr 6, 2026

Study contacts

Marc Toeteberg-Harms, MD
Contact
marc-toeteberg-harms@uiowa.edu
+1 319 356 3938
Helen Gomez Study Coordinator
Contact
helen-gomez@uiowa.edu
+1 319 356 3938

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion